Centre for Psychedelics Health & Research

The Centre for Psychedelics Health and Research at Providence Care is among the first of its kind in Canada. It approaches psychedelic science in a comprehensive way, by providing a nationwide platform for clinical trials, training opportunities for healthcare providers and researchers, and knowledge mobilization initiatives with clinicians, community members, and policy makers. It aims to overcome the stigma often associated with the therapeutic use of psychedelics in a health care setting, while serving as a hub for research, education, training and treatment,  from experts  across Canada and internationally.

Evolving from a psychedelics research collaborative founded at Queen’s University in 2001, with support from Ontario Brain Institute and the Canadian Biomarker Integration Network in Depression (CAN-BIND), the Centre for Psychedelics Health and Research at Providence Care is a multidisciplinary hub. It connects local and national partners across various disciplines as they explore the therapeutic use of psychedelics as treatment for mental illness, substance use disorders, chronic pain, and palliative needs.

The Centre for Psychedelics Health and Research fits Providence Care’s mission of instilling hope and enhancing the quality of life in the people served through partnership and innovation. The Centre not only represents hope for those with treatment-resistant conditions, but also underscores Providence Care’s commitment to leading-edge research and patient and client care. Allison Philpot, Vice President System Innovation and Executive Director, Medical Affairs & Research looks forward to the positive impact this Centre has on individuals and communities, both locally and beyond.